CDKN2A and esophageal squamous cell carcinoma: Overall, our results demonstrated that dysfunctions in the p53 and Cdk4/6-p16-Rb cell cycle checkpoint control pathways, especially the Cdk4/6-p16-Rb cell cycle checkpoint control pathway, increase the vulnerability of ESCC cells to ART treatment.